| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4aba5130b481ea5be1710d495eac3cad |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0402
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D225-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D225-08 |
| filingDate |
2017-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_108c1f4925e7abff54fa360ffbefc7a1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d42ff08ebb9aafc48a00d34a7d17af75 |
| publicationDate |
2019-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3544960-A1 |
| titleOfInvention |
Albumin-binding psma inhibitors |
| abstract |
Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L1 and L2 are each independently a covalent bond or a divalent linking group, R is a detectable label or therapeutic drug and B is an albumin binding moiety. Also provided are compositions including a compound of Formula (I) together with a pharmaceutically acceptable carrier, and methods for imaging prostate cancer cells using a compound of Formula (I). |
| priorityDate |
2016-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |